• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

US Court Ruling Casts Gene Patenting Into Doubt

30/03/2010 by Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

A New York federal court ruled yesterday that patents on genes associated with hereditary breast and ovarian cancer are invalid, in the first time a court decided that patents on genes are unlawful, according to the American Civil Liberties Union (ACLU).

ACLU and the Public Patent Foundation represented a group of patients and scientists in the lawsuit brought to court in May 2009 against Myriad Genetics and the University of Utah Research Foundation, which hold the patents on the BRCA genes. The lawsuit was also brought against the US Patent and Trademark Office (IPW, Biodiversity/Genetic Resources/Biotech, 2 September 2009).

The ruling [pdf] is a victory for the free flow of ideas in scientific research,” said Chris Hansen, staff attorney with ACLU, in a release. The court granted the USPTO’s request to be released as a defendant in the lawsuit since the court decided that because of the favourable ruling in favour of the plaintiff, there was no need to reach the First Amendment claims against the office.

The outcome of the ruling could have “far reaching impact,” according to ACLU, since the grounds of the lawsuit was the notion of patents on human genes.

In February, a US health department advisory group released recommendations unfavourable to patents on genes in the US, presenting them as negatively impacting patients’ access to genetic tests (IPW, Biodiversity/Genetic Resources/Biotech, 10 February 2010).

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"US Court Ruling Casts Gene Patenting Into Doubt" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, Language, English

Trackbacks

  1. US IP Enforcement Ambitions In Trans-Pacific Trade Agreement Stir Reactions | Intellectual Property Watch says:
    16/03/2011 at 4:31 pm

    […] patents on genes and in particular genetic diagnostics are currently under challenge in the US (IPW, IP Live, 30 March 2010), the US proposal appears to call for broad patentability […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2021 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.